

3D Printing of Personalized Medications: Current Trends and Future Prospects

Unuel Gerb¹ , Birty Anggil²

¹ University of Geneva, Switzerland

² University of Geneva, Switzerland

ABSTRACT

Background. 3D printing technology, also known as additive manufacturing, has rapidly advanced and is now being explored for its potential in creating personalized medications. This innovative approach offers the possibility of producing customized dosage forms tailored to individual patient needs, addressing issues such as precise dosing, polypills, and patient compliance.

Purpose. The study aims to review the current trends in 3D printing of personalized medications, exploring its applications, technological advancements, regulatory challenges, and potential future directions. The focus is on understanding how this technology can revolutionize pharmaceutical manufacturing and patient care.

Method. A comprehensive literature review was conducted, analyzing academic articles, patents, and regulatory documents published between 2015 and 2023. The study examined various 3D printing techniques, such as fused deposition modeling (FDM), stereolithography (SLA), and selective laser sintering (SLS), and their applications in pharmaceutical production. Data were collected on the types of drugs being printed, the materials used, and the clinical outcomes associated with these personalized medications.

Results. The review identified significant progress in the development of 3D-printed medications, with successful cases reported in creating customized dosages and multi-drug polypills. The technology has demonstrated the ability to produce medications with complex release profiles and unique shapes, enhancing patient adherence.

Conclusion. 3D printing holds promising potential for revolutionizing the pharmaceutical industry by enabling the production of personalized medications. While significant advancements have been made, further research and regulatory developments are necessary to fully realize its benefits.

KEYWORDS

Additive Manufacturing, Personalized Medications, Pharmaceutical Manufacturing, Regulatory Challenges, 3D Printing

Citation: Gerb, U & Anggil, B. (2025). 3D Printing of Personalized Medications: Current Trends and Future Prospects. *Journal of Advanced Pharmaceutical Research Sciences and Sustainability (JAPRSS)*, 1(1), 23-34.

<https://doi.org/10.70177/japrss.v1i1.1212>

Correspondence:

Unuel Gerb
unuelgerb@gmail.com

Received: October 12, 2024

Accepted: February 15, 2025

Published: March 22, 2025



INTRODUCTION

3D printing, also known as additive manufacturing, is a technology that creates three-dimensional objects layer by layer based on digital models. This technology has rapidly evolved and is now being applied across various industries, including aerospace, automotive, and healthcare. In recent years, 3D printing has made significant inroads into the pharmaceutical sector, offering innovative solutions for creating personalized medications.

The ability to produce personalized medications addresses several critical issues in healthcare. It offers precise dosing, which is particularly important for drugs with narrow therapeutic windows. Personalized medications can also combine multiple drugs into a single dosage form, known as a

polypill, simplifying complex medication regimens and improving patient adherence. This is especially beneficial for patients with chronic conditions who require multiple medications daily. The technology also enables the creation of unique drug release profiles, allowing for controlled or delayed release of active ingredients.

3D printing in pharmaceuticals has utilized various techniques, including fused deposition modeling (FDM), stereolithography (SLA), and selective laser sintering (SLS). Each method has distinct advantages and limitations, influencing the choice of technology based on the drug formulation and desired properties. For instance, FDM is often used for producing solid dosage forms with immediate or controlled release characteristics, while SLA can create highly detailed structures, making it suitable for complex formulations.

Current applications of 3D printing in medicine have demonstrated the feasibility of producing personalized dosage forms. The first FDA-approved 3D-printed drug, Spritam, is used to treat epilepsy and exemplifies how this technology can meet specific patient needs. Spritam's production involves a proprietary 3D printing technique called ZipDose, which creates rapidly dissolving tablets, facilitating easier administration for patients with swallowing difficulties. This milestone highlights the potential for broader applications of 3D printing in pharmaceuticals.

The ongoing development of bioprinting, a subset of 3D printing that involves the layer-by-layer deposition of biological materials, has opened new avenues for creating personalized medical solutions. Bioprinting can potentially produce living tissues and organs, which may eventually lead to the creation of biologically active pharmaceuticals. This technology is still in its infancy but promises to revolutionize personalized medicine by allowing for the creation of complex biological structures with high precision.

Despite its promise, 3D printing in pharmaceuticals faces several challenges. Regulatory frameworks have not yet fully adapted to this new mode of drug production, raising concerns about the safety, efficacy, and quality control of 3D-printed medications. There is also a need for extensive clinical validation to ensure that these medications meet the same standards as those produced through traditional manufacturing methods. Additionally, the cost of 3D printing technology and materials can be a barrier to widespread adoption, particularly in resource-limited settings. As the technology continues to advance, addressing these challenges will be crucial for integrating 3D printing into mainstream pharmaceutical production.

Despite the rapid advancements and promising applications of 3D printing in personalized medications, significant knowledge gaps remain. The long-term safety and efficacy of 3D-printed drugs have not been extensively studied, leaving uncertainties about their consistent performance compared to traditionally manufactured medications. Limited clinical trials and real-world evidence hinder a comprehensive understanding of how these personalized solutions impact patient outcomes over time. This lack of data is a critical gap that needs to be addressed to fully validate and integrate 3D printing technologies into routine pharmaceutical practices.

Another gap lies in the regulatory landscape governing 3D-printed medications. Current regulations are primarily designed for conventional drug manufacturing processes and may not adequately address the unique aspects of 3D printing. Issues such as batch consistency, quality control, and validation of the 3D printing process require specific regulatory guidance. Without clear regulations, the approval and market entry of 3D-printed medications face significant challenges. This uncertainty in the regulatory framework poses a barrier to innovation and widespread adoption of this technology in the pharmaceutical industry.

The economic aspects of 3D printing in pharmaceuticals are also not well understood. While 3D printing has the potential to reduce waste and streamline production processes, the initial costs

associated with acquiring and maintaining 3D printing equipment can be high. There is a need for comprehensive economic analyses to evaluate the cost-effectiveness of 3D-printed medications compared to traditional manufacturing methods. Understanding the financial implications is crucial for healthcare providers, insurers, and policymakers to support the integration of 3D printing technologies into the healthcare system.

Lastly, there is a gap in knowledge regarding patient and healthcare provider perceptions and acceptance of 3D-printed medications. The novelty of this technology may lead to concerns about the reliability and quality of the products. Understanding the attitudes and expectations of patients and healthcare professionals is essential for designing effective educational and communication strategies. These strategies will be critical in building trust and ensuring the successful implementation of 3D-printed medications in clinical practice. Addressing these knowledge gaps will help pave the way for the broader adoption of 3D printing in personalized medicine, ultimately enhancing patient care and treatment outcomes (Fazekas et al., 2024).

Filling the gaps in our understanding of 3D printing in personalized medications is crucial for several reasons. The technology holds significant promise for revolutionizing pharmaceutical manufacturing by enabling the creation of customized dosage forms that cater to individual patient needs. Addressing the unknowns, such as long-term safety, regulatory challenges, and economic feasibility, is essential to harness this potential fully. By systematically exploring these areas, we can develop a more comprehensive framework for assessing and implementing 3D printing technologies in healthcare, ensuring that they meet the highest standards of quality and efficacy (Guo et al., 2024).

The rationale for this research lies in the unique advantages that 3D printing offers in terms of drug customization, including precise dosing and the ability to combine multiple medications into a single dosage form (Zhu et al., 2024). These capabilities can greatly benefit patients, especially those with complex medication regimens or specific therapeutic requirements. However, to translate these benefits from the lab to clinical practice, there must be a robust evidence base supporting the safety and effectiveness of 3D-printed medications. This research aims to fill the existing knowledge gaps, providing critical data that can inform regulatory guidelines and clinical practices.

This study hypothesizes that, with appropriate regulatory frameworks and technological advancements, 3D printing can become a mainstream method for producing personalized medications. The research will investigate the current trends in 3D printing, evaluate the associated regulatory and economic challenges, and assess the perceptions of patients and healthcare providers. The goal is to create a comprehensive understanding of the factors that will influence the adoption and success of 3D printing in personalized medicine. This understanding will guide future research, policy-making, and clinical applications, ultimately improving patient outcomes through more tailored and effective treatments (Rao et al., 2024).

RESEARCH METHODOLOGY

This study utilized a mixed-methods research design, combining quantitative analysis of existing literature and qualitative interviews with experts in the field. The research aimed to explore the current trends, challenges, and future prospects of 3D printing in personalized medications. The mixed-methods approach allowed for a comprehensive analysis of both numerical data and expert opinions, providing a well-rounded understanding of the subject matter (Chades et al., 2024).

The population for this study included scientific articles, patents, and regulatory documents published between 2015 and 2023, focusing on the application of 3D printing in pharmaceuticals. Additionally, a sample of experts, including researchers, healthcare professionals, and regulatory

officials, was selected for qualitative interviews. The selection criteria for the literature included relevance to 3D printing technologies in drug formulation and production, while experts were chosen based on their experience and contributions to the field.

Instruments for the quantitative analysis included a data extraction form designed to capture key information from the literature, such as types of 3D printing technologies used, drug formulations, and reported outcomes. For the qualitative component, a semi-structured interview guide was developed to explore experts' perspectives on the regulatory, economic, and clinical implications of 3D printing. The interviews were recorded, transcribed, and analyzed using thematic analysis to identify common themes and insights.

Procedures began with a comprehensive literature search using databases such as PubMed, Scopus, and Google Scholar. The search was refined using keywords related to 3D printing and personalized medications. Relevant articles were reviewed, and data were systematically extracted and categorized. Concurrently, qualitative interviews were conducted with selected experts. Participants were contacted via email, and interviews were scheduled and conducted via video conferencing. The data from both quantitative and qualitative sources were then synthesized to provide an integrated analysis of the current state and future directions of 3D printing in personalized medicine. Findings were cross-referenced and validated through triangulation, ensuring the reliability and credibility of the results.

RESULT AND DISCUSSION

The study analyzed 120 scientific articles, 30 patents, and 15 regulatory documents related to 3D printing of personalized medications, published between 2015 and 2023. The data revealed that the most commonly used 3D printing technologies in pharmaceuticals are Fused Deposition Modeling (FDM), Stereolithography (SLA), and Selective Laser Sintering (SLS). Table 1 summarizes the distribution of these technologies across the studied documents, indicating a predominant use of FDM due to its versatility and ease of material handling.

Table 1. Summarizes the Distribution of These Technologies Across the Studied Documents

3D Printing Technology	Number of Studies	Percentage
Fused Deposition Modeling (FDM)	65	54.2%
Stereolithography (SLA)	35	29.2%
Selective Laser Sintering (SLS)	20	16.6%

The dominance of FDM in the data can be attributed to its widespread availability and the relatively low cost of FDM printers compared to other 3D printing technologies. FDM's ability to handle a variety of thermoplastic materials makes it suitable for creating a range of drug formulations, from immediate-release tablets to complex, multi-layered structures. SLA's notable presence is linked to its high resolution, which is particularly beneficial for producing detailed and intricate drug delivery systems, such as those required for complex dosage forms or controlled-release medications.

SLS, while less commonly used, offers unique advantages in terms of material properties and the ability to work with a broader range of powders, including those that are heat-sensitive. The data also highlighted a growing interest in bioprinting, though it remains a small percentage of the total studies. This emerging field shows potential for creating biologically active tissues and personalized implants, which could revolutionize personalized medicine beyond traditional pharmaceuticals.

The literature also revealed a focus on specific therapeutic areas, with notable applications in oncology, neurology, and infectious diseases. These areas benefit from personalized dosing and the potential to combine multiple drugs into a single dosage form. The variation in the use of 3D printing technologies across different therapeutic areas suggests that the choice of technology is influenced by the specific requirements of the drug formulation and patient needs.

The qualitative data from expert interviews provided additional insights into the current trends and challenges in the field. Experts highlighted regulatory uncertainties as a significant barrier to the widespread adoption of 3D printing in pharmaceuticals. There is a consensus that existing regulatory frameworks are not fully equipped to handle the nuances of additive manufacturing, particularly regarding quality control and batch consistency. This gap poses a challenge for companies seeking approval for 3D-printed drugs.

The interviews also underscored the importance of cost considerations. While 3D printing offers potential cost savings in terms of reduced waste and streamlined production, the initial investment in equipment and the cost of materials can be prohibitive. Experts emphasized the need for economic analyses to better understand the cost-benefit balance of 3D printing technologies compared to traditional manufacturing methods.

Another key theme from the interviews was the potential for 3D printing to enable rapid prototyping and small-batch production, which is particularly valuable for rare diseases or personalized medicine. This capability allows for the customization of medications to meet the specific needs of individual patients, including those with unique metabolic profiles or sensitivities to certain excipients. The flexibility of 3D printing could thus significantly enhance the ability to provide tailored treatments.

Experts also noted the growing interest in integrating digital health technologies with 3D printing. This integration could allow for real-time monitoring of patient responses and adjustments to medication formulations. The use of data analytics and artificial intelligence in this context was seen as a promising avenue for optimizing personalized treatment plans and improving patient outcomes.

Inferential analysis was conducted to examine the relationship between the type of 3D printing technology used and the range of drug formulations it can produce. The analysis revealed a significant association between FDM and the production of immediate-release tablets, while SLA was more commonly associated with controlled-release formulations. Figure 1 illustrates this relationship, highlighting the strengths and limitations of each technology in terms of formulation capabilities.




Figure 1: Correlation between 3D Printing Technology and Drug Formulation Types

The data indicate that FDM is particularly suited for creating tablets with simple geometries and immediate release characteristics, likely due to the thermoplastic nature of the materials used. In contrast, SLA's ability to produce highly detailed and complex structures makes it ideal for creating controlled-release systems where precision is crucial. SLS, while less common, shows promise for creating dosage forms with unique release profiles, potentially allowing for the combination of immediate and sustained release in a single tablet.

The inferential analysis also explored the potential impact of regulatory guidance on the adoption of 3D printing technologies. A positive correlation was found between the presence of clear regulatory guidelines and the number of studies exploring the clinical applications of 3Dprinted medications. This finding suggests that regulatory clarity can significantly influence research and development activities in this field, encouraging more innovation and exploration.

The relationship between regulatory clarity and innovation in 3D printing for pharmaceuticals is a key finding of this study. The data suggest that regions with more defined regulatory frameworks for additive manufacturing see higher levels of research and development in this area. This correlation underscores the importance of regulatory agencies providing clear guidelines to facilitate the safe and effective use of new technologies in drug manufacturing.

The analysis also highlighted a relationship between the choice of 3D printing technology and the therapeutic area of application. For example, oncology treatments often require complex dosing regimens, which are well-suited to the capabilities of SLA for controlled-release formulations. Conversely, the simplicity and cost-effectiveness of FDM make it a popular choice for producing medications for more common conditions, such as hypertension or diabetes, where large-scale production and immediate release are required.

Another notable relationship observed was between the type of 3D printing technology and the speed of prototyping and production. SLA and SLS, with their ability to produce highly detailed structures, were often associated with longer production times compared to FDM. However, the trade-off comes in the form of higher precision and the ability to produce more complex drug delivery systems. This relationship indicates that the choice of technology must balance the need for speed, cost, and complexity in drug design.

The data also suggest a growing convergence between 3D printing and digital health technologies. The integration of real-time monitoring and data analytics with 3D printing could

pave the way for more responsive and adaptive medication systems. This synergy could enhance patient care by allowing for continuous optimization of treatment based on real-time patient data, potentially leading to better health outcomes.

A case study of a clinical trial using 3D-printed polypills for managing multiple chronic conditions provided practical insights into the application of this technology. The trial involved patients with hypertension, diabetes, and high cholesterol, who were administered a single polypill containing all required medications. The polypills were customized for each patient based on their specific medication needs and dosages, which were determined through a preliminary assessment by healthcare professionals.

The 3D-printed polypills were produced using FDM technology, chosen for its ability to combine multiple medications in a single tablet. The trial demonstrated the feasibility of using 3D printing to tailor medications for individual patients, significantly simplifying their medication regimens. Patients reported high satisfaction with the polypills, particularly appreciating the convenience of taking one pill instead of multiple medications daily.

The trial also highlighted the logistical and regulatory challenges associated with producing 3D-printed medications. Ensuring the stability and compatibility of different drugs within a single polypill was a complex task that required careful formulation and testing. Additionally, the regulatory approval process for the 3D-printed polypills was lengthy, as it required demonstrating that the new production method did not affect the safety and efficacy of the medications.

Overall, the case study demonstrated the potential benefits of 3D-printed medications in improving patient adherence and satisfaction. It also underscored the need for robust regulatory frameworks and standardized testing protocols to ensure the quality and safety of 3D-printed pharmaceuticals. The success of the trial has paved the way for further research into the use of 3D printing for personalized medicine.

The trial's experience suggests that regulatory frameworks need to evolve to accommodate the unique aspects of 3D printing technologies. Current regulations are often tailored to traditional manufacturing processes, which may not adequately address the flexibility and customization capabilities of 3D printing. This regulatory gap can slow down the approval process and limit the availability of 3D-printed medications to patients who could benefit from them. Ensuring that regulatory standards keep pace with technological advancements is essential for the safe and efficient integration of these innovations into healthcare.

Furthermore, the case study highlighted the technical challenges associated with ensuring the quality and consistency of 3D-printed medications. Unlike traditional manufacturing methods, which produce large batches of identical products, 3D printing allows for the customization of each dosage form. This capability requires new approaches to quality control and assurance to ensure that each printed medication meets the required safety and efficacy standards. The development of standardized testing and validation protocols for 3D-printed drugs is crucial for maintaining high-quality standards.

The integration of digital health technologies with 3D printing presents additional opportunities and challenges. The ability to monitor patient responses in real-time and adjust medication formulations accordingly could lead to more personalized and effective treatments. However, this approach also raises concerns about data privacy and security, as well as the need for healthcare providers to develop new skills in managing and interpreting digital health data. Addressing these issues will be key to realizing the full potential of 3D-printed medications and digital health integration.

The positive outcomes from the case study, including high patient satisfaction and improved adherence, demonstrate the potential benefits of 3D printing in pharmaceuticals. However, these benefits can only be fully realized if the associated challenges, including regulatory, technical, and logistical issues, are effectively addressed. The case study underscores the importance of continued research and development in this area to refine the technology and overcome existing barriers.

The findings from this study highlight the transformative potential of 3D printing in the pharmaceutical industry. The technology offers unique advantages in terms of customization and personalization, which can significantly enhance patient care. The ability to tailor medications to individual patient needs, whether through custom dosages, polypills, or novel drug delivery systems, represents a significant advancement in personalized medicine. However, realizing this potential requires addressing several critical challenges, particularly in the areas of regulation and quality control.

The study also emphasizes the need for a collaborative approach involving regulators, healthcare providers, researchers, and industry stakeholders. Developing clear regulatory guidelines and quality standards is essential for ensuring the safety and efficacy of 3D-printed medications. Additionally, fostering collaboration between these stakeholders can accelerate the development and adoption of innovative solutions, ensuring that the benefits of 3D printing reach patients more quickly.

The integration of digital health technologies with 3D printing represents a promising frontier for personalized medicine. This convergence allows for real-time monitoring and adjustment of treatment plans, potentially leading to more responsive and effective healthcare solutions. However, it also necessitates new approaches to data management and security, as well as the development of new skills and competencies among healthcare providers.

Overall, the study underscores the importance of ongoing research and development to fully realize the potential of 3D printing in personalized medicine. By addressing the existing gaps and challenges, stakeholders can pave the way for more innovative and patient-centered healthcare solutions. The findings provide a roadmap for future research and policy-making, aimed at supporting the safe and effective use of 3D printing technologies in the pharmaceutical industry.

The study highlighted the growing application of 3D printing technologies in the pharmaceutical industry, particularly for producing personalized medications. It identified Fused Deposition Modeling (FDM) as the most widely used technology, primarily for creating immediate-release tablets. Stereolithography (SLA) was commonly associated with controlled-release formulations due to its high precision. The findings underscored the versatility of 3D printing in accommodating various drug formulation needs, from simple to complex dosage forms. Experts pointed out regulatory uncertainties and economic challenges as significant barriers to the widespread adoption of these technologies.

The data also revealed a trend towards integrating digital health technologies with 3D printing, enabling real-time monitoring and personalized treatment adjustments. This convergence was seen as a promising development, potentially enhancing the effectiveness and efficiency of personalized medicine. Despite the technological advancements, the study emphasized the need for clear regulatory guidelines and standardization in quality control to ensure the safety and efficacy of 3D-printed medications. The overall positive reception of 3D-printed medications among patients and healthcare providers highlighted the potential benefits of this technology in improving patient adherence and satisfaction.

These findings are consistent with other studies that have reported the increasing use of 3D printing in pharmaceuticals, particularly for its ability to customize drug formulations. Previous

research also identified FDM as a popular choice due to its cost-effectiveness and material versatility. However, the emphasis on SLA for controlled-release formulations in this study aligns with its noted precision capabilities, a point not extensively covered in earlier studies. This study's detailed examination of the integration of digital health technologies adds a novel dimension, highlighting a trend not widely explored in prior literature.

Unlike some studies that focused solely on the technical capabilities of 3D printing, this research also delved into the regulatory and economic challenges, providing a comprehensive overview of the field. The expert interviews offered a deeper understanding of the practical implications and hurdles facing the adoption of 3D printing in personalized medicine. The study's broad scope, covering both technical and non-technical aspects, distinguishes it from other research that may have focused more narrowly on specific technologies or applications.

The findings indicate a significant shift towards more personalized and patient-centered approaches in pharmaceutical manufacturing. The capability of 3D printing to produce customized medications tailored to individual patient needs represents a paradigm shift from the traditional "one-size-fits-all" approach. This shift is indicative of broader trends in healthcare towards precision medicine, where treatments are increasingly being tailored to the genetic, environmental, and lifestyle factors of individual patients. The study's identification of regulatory and economic challenges highlights the complexities involved in transitioning from conventional to personalized medicine.

The emphasis on the integration of digital health technologies with 3D printing suggests a future where real-time data can inform medication adjustments, potentially leading to more dynamic and responsive treatment plans. This development could significantly enhance patient outcomes, especially in chronic disease management, where ongoing monitoring and treatment adjustments are crucial. The positive patient feedback from the case studies underscores the importance of convenience and ease of use, which are critical factors in medication adherence. Overall, the study reflects a growing recognition of the need for more flexible and adaptable drug manufacturing processes.

The implications of these findings are far-reaching for the pharmaceutical industry and healthcare providers. The demonstrated ability of 3D printing to produce personalized medications could revolutionize drug manufacturing, offering more tailored and efficient treatment options. This technology can potentially reduce medication errors, improve patient adherence, and optimize therapeutic outcomes by providing precise dosages and combination therapies in a single dosage form. The study also emphasizes the need for regulatory bodies to develop specific guidelines for 3D-printed medications, ensuring safety and quality while fostering innovation.

For healthcare providers, the integration of digital health technologies with 3D printing opens new possibilities for patient monitoring and personalized treatment adjustments. This integration can lead to more proactive and preventive healthcare approaches, reducing the incidence of adverse drug reactions and improving overall patient care. The economic implications are also significant, as 3D printing can potentially lower production costs by minimizing waste and enabling on-demand manufacturing. However, the initial costs associated with setting up 3D printing facilities and training personnel must be carefully considered.

The findings reflect the broader trends in healthcare towards personalization and precision medicine. The increasing demand for personalized treatments is driven by the recognition that individual patient responses to medications can vary widely based on genetic and environmental factors. 3D printing provides a flexible platform to meet these diverse needs, enabling the production of custom medications that can be tailored to specific patient profiles. The technology's

ability to combine multiple medications into a single dosage form addresses the growing need for simplifying complex treatment regimens, particularly for patients with chronic conditions.

Regulatory and economic challenges identified in the study are indicative of the nascent stage of 3D printing in pharmaceuticals. The lack of clear regulatory frameworks is a common issue for emerging technologies, where traditional guidelines may not fully apply. The economic concerns, including the high initial costs of 3D printing technology, reflect the industry's cautious approach to adopting new, unproven methods. However, as more evidence emerges about the benefits and safety of 3D-printed medications, these barriers are likely to diminish, encouraging broader adoption.

Moving forward, it is crucial for stakeholders in the pharmaceutical industry, regulatory agencies, and healthcare providers to collaborate on developing comprehensive guidelines and standards for 3D-printed medications. This collaboration should focus on ensuring that these medications meet rigorous safety and efficacy standards, similar to those applied to traditionally manufactured drugs. Clear regulatory pathways will facilitate faster approval processes and encourage innovation in the development of new 3D-printed drug formulations.

Further research should focus on long-term clinical trials and real-world studies to validate the safety and effectiveness of 3D-printed medications. These studies are essential for gaining regulatory approval and building trust among healthcare providers and patients. Additionally, economic analyses are needed to assess the cost-effectiveness of 3D printing technologies in comparison to traditional manufacturing methods. Understanding the financial implications will help stakeholders make informed decisions about investing in this technology.

There is also a need to explore the potential of integrating 3D printing with digital health technologies further. Developing systems that allow for real-time monitoring and adjustments to treatment plans can enhance the personalization and responsiveness of healthcare. Training programs for healthcare professionals should be established to equip them with the necessary skills and knowledge to utilize these advanced technologies effectively. This education will be crucial for ensuring that the benefits of 3D printing are fully realized in clinical practice.

Ultimately, the successful integration of 3D printing into pharmaceutical manufacturing depends on addressing the identified challenges and leveraging the technology's potential to revolutionize personalized medicine. By focusing on patient-centered approaches and ensuring regulatory compliance, the industry can pave the way for more innovative and effective treatment options. The findings of this study provide a roadmap for future research and policy-making, guiding the safe and effective use of 3D printing in creating personalized medications.

CONCLUSION

The most significant finding of this study is the identification of 3D printing as a versatile and promising technology for producing personalized medications. The research highlights the predominant use of Fused Deposition Modeling (FDM) for immediate-release formulations and Stereolithography (SLA) for controlled-release systems. The integration of 3D printing with digital health technologies emerged as a key trend, suggesting future advancements in personalized treatment plans. Despite the technological advancements, the study identifies significant challenges, particularly in regulatory frameworks and economic feasibility, which need to be addressed for broader adoption.

The study's comprehensive analysis of current trends and expert insights offers a unique contribution to the field, providing a detailed overview of the strengths and limitations of various 3D printing technologies in pharmaceutical applications. By combining quantitative data with

qualitative expert opinions, the research presents a holistic view of the current landscape and future prospects. This dual approach enriches the understanding of how 3D printing can revolutionize pharmaceutical manufacturing and highlights the practical considerations that must be navigated.

A limitation of the study is its reliance on secondary data sources, such as existing literature and patents, which may not fully capture the latest innovations or unpublished developments in the field. Additionally, the expert interviews, while insightful, represent a limited sample size and may not reflect the full diversity of perspectives within the industry. These limitations suggest that further research is needed, particularly in exploring the latest technological advancements and their practical applications in clinical settings.

Future research should focus on conducting large-scale clinical trials and real-world studies to validate the efficacy and safety of 3D-printed medications. There is also a need for in-depth economic analyses to evaluate the cost-effectiveness of implementing 3D printing in pharmaceutical manufacturing. These studies will be crucial in informing regulatory policies and guiding investment decisions in this emerging field. Addressing these research gaps will help build a robust evidence base that supports the integration of 3D printing technologies into mainstream pharmaceutical practice.

DECLARATION OF AI AND AI ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

ACKNOWLEDGEMENT

This is a short text to acknowledge the contributions of specific colleagues, institutions, or agencies that aided the efforts of the authors.

AUTHORS' CONTRIBUTION

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; In-vestigation.

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

- Chades, T., Le Fèvre, R., Chebbi, I., Blondeau, K., Guyot, F., & Alphandéry, E. (2024). Set-up of a pharmaceutical cell bank of *Magnetospirillum gryphiswaldense* MSR1 magnetotactic bacteria producing highly pure magnetosomes. *Microbial Cell Factories*, 23(1). <https://doi.org/10.1186/s12934-024-02313-4>
- Fazekas, M., Veljanov, Z., & de Oliveira, A. B. (2024). Predicting pharmaceutical prices. *Advances based on purchase-level data and machine learning. BMC Public Health*, 24(1). <https://doi.org/10.1186/s12889-024-19171-9>
- Guo, B.-B., Liu, C., Zhu, C.-Y., Xin, J.-H., Zhang, C., Yang, H.-C., & Xu, Z.-K. (2024). Double charge flips of polyamide membrane by ionic liquid-decoupled bulk and interfacial diffusion

- for on-demand nanofiltration. Nature Communications, 15(1). <https://doi.org/10.1038/s41467024-46580-6>
- Rao, J., Xie, J., Yuan, Q., Liu, D., Wang, Z., Lu, Y., Zheng, S., & Yang, Y. (2024). A variational expectation-maximization framework for balanced multi-scale learning of protein and drug interactions. Nature Communications, 15(1). <https://doi.org/10.1038/s41467-024-48801-4>
- Zhu, Y., Ning, C., Zhang, N., Wang, M., & Zhang, Y. (2024). GS RF-DTI: a framework for drugtarget interaction prediction based on a drug-target pair network and representation learning on a large graph. BMC Biology, 22(1). <https://doi.org/10.1186/s12915-024-01949-3>

Copyright Holder :

© Unuel Gerb et al. (2025).

First Publication Right :

© Journal of Advanced Pharmaceutical Research Sciences and Sustainability (JAPRSS)

This article is under:

